Beta-2 Crosslaps CTx-1, EDTA Plasma

Bone

Report in 144Hrs

At Home

No Fasting Required

Details

Marker of bone resorption.

₹2,294₹3,277

30% OFF

Beta-2 Crosslaps CTx-1 EDTA Plasma Test Guide

Why is it done?
- Measures bone resorption markers: This test quantifies CTx (C-terminal telopeptide of type I collagen), a specific breakdown product released during bone resorption, indicating the rate of bone turnover and osteoclast activity
- Diagnose and monitor osteoporosis: Assesses bone loss severity and fracture risk in patients with suspected or confirmed osteoporosis
- Monitor bone-modifying therapy: Evaluates treatment response in patients receiving medications for osteoporosis, such as bisphosphonates, denosumab, or hormone replacement therapy
- Assess bone metabolism disorders: Identifies abnormal bone turnover in conditions such as Paget's disease, hyperthyroidism, and metabolic bone diseases
- Predict fracture risk: Provides early indication of accelerated bone loss and helps stratify fracture risk in postmenopausal women and aging populations
- Typical timing: Performed at baseline for osteoporosis assessment, then repeated every 3-6 months during treatment to monitor therapeutic response or every 6-12 months for surveillance
Normal Range
- Reference values (laboratory-dependent): Typically range from 0.4 to 0.9 ng/mL in adults, with variations based on age, sex, and menopausal status
- Sex-specific differences: Women typically have higher values (0.5-1.0 ng/mL) compared to men (0.4-0.8 ng/mL) due to hormonal influences on bone metabolism
- Age-related variations: Values may increase with advancing age and are significantly elevated in postmenopausal women due to declining estrogen levels
- Unit of measurement: ng/mL (nanograms per milliliter) or μg/L (micrograms per liter)
- Normal vs. abnormal interpretation: Normal values suggest appropriate bone turnover; elevated levels indicate accelerated bone resorption and increased fracture risk; low values after treatment suggest effective therapy
- Biological variation: Values demonstrate diurnal variation and seasonal fluctuations; early morning fasting samples provide most consistent and comparable results
Interpretation
- Elevated levels (>1.0 ng/mL): Indicate accelerated bone resorption and high bone turnover, suggesting increased fracture risk; common in postmenopausal women, hyperthyroidism, and active osteoporosis
- Markedly elevated levels (>1.5 ng/mL): Suggest severe bone loss, possible secondary osteoporosis, or inadequately treated primary osteoporosis; warrant investigation for underlying causes
- Normal range (0.4-0.9 ng/mL): Reflects appropriate bone turnover with lower fracture risk; reassuring in patients at risk for osteoporosis
- Rapid decrease after treatment initiation (>30% reduction): Indicates favorable therapeutic response to bone-modifying therapy; suggests medications are effectively suppressing bone resorption
- Persistent elevation or lack of response: May indicate poor medication adherence, inadequate dosing, or need for alternative therapeutic approach
- Factors affecting interpretation: Circadian rhythm (highest in early morning), menstrual cycle phase in premenopausal women, recent physical activity, medications (corticosteroids, thyroid hormones), renal function, and malabsorption disorders
- Correlation with other markers: Should be interpreted alongside P1NP (bone formation marker), alkaline phosphatase, calcium, phosphate, and vitamin D levels for comprehensive bone metabolism assessment
- Clinical significance: Early indicator of fracture risk; more sensitive to therapy changes than bone density measurements; useful for monitoring compliance and therapeutic efficacy
Associated Organs
- Primary organ system: Skeletal system (bones) - test directly reflects osteoclast activity and bone resorption throughout the skeleton
- Secondary organ involvement: Kidney function affects CTx metabolism and clearance; liver metabolism influences vitamin D activation; endocrine organs (parathyroid, thyroid, gonads) regulate bone turnover
- Osteoporosis: Most common condition; characterized by decreased bone mineral density and increased fracture risk; elevated CTx indicates accelerated bone loss
- Postmenopausal bone loss: Dramatic increase in CTx due to estrogen deficiency; typically elevated 2-3 fold compared to premenopausal levels
- Paget's disease of bone: Severe elevation of CTx reflecting intense focal bone resorption and abnormal bone turnover
- Hyperthyroidism: Excess thyroid hormone accelerates bone resorption, causing markedly elevated CTx levels
- Primary hyperparathyroidism: Elevated PTH increases bone resorption; CTx serves as marker of disease severity and surgical necessity
- Chronic kidney disease: Altered mineral metabolism elevates CTx; renal insufficiency impairs CTx clearance
- Multiple myeloma and bone metastases: Increased osteoclastic activity; elevated CTx indicates aggressive bone involvement
- Complications of abnormal results: High CTx levels increase risk of osteoporotic fractures (hip, spine, wrist, humerus); compromised quality of life and mobility; potential for serious complications from falls and fractures
Follow-up Tests
- P1NP (Procollagen Type 1 N-terminal Propeptide): Complementary bone formation marker; should be ordered alongside CTx for comprehensive bone turnover assessment
- Bone-specific alkaline phosphatase (BSAP): Additional bone formation marker providing independent assessment of osteoblast activity
- DEXA scan (Dual Energy X-ray Absorptiometry): Measure bone mineral density; provides definitive osteoporosis diagnosis and baseline fracture risk stratification
- Serum calcium and phosphate: Essential for evaluating mineral metabolism disorders; detect hypercalcemia or hyperphosphatemia
- 25-hydroxyvitamin D [25(OH)D]: Assesses vitamin D status; deficiency contributes to bone loss and secondary hyperparathyroidism
- Parathyroid hormone (PTH): Evaluates parathyroid function; elevated PTH explains accelerated bone resorption
- Thyroid-stimulating hormone (TSH) and free T4: Screen for hyperthyroidism affecting bone metabolism
- Renal function tests (creatinine, eGFR): Evaluate kidney function affecting CTx clearance and mineral metabolism
- Liver function tests: Assess vitamin D metabolism and synthetic function
- Complete blood count (CBC): Screen for anemia or malignancy affecting bone metabolism
- Tissue transglutaminase (tTG) or tissue transglutaminase total IgA: Screen for celiac disease contributing to malabsorption and osteoporosis
- Monitoring frequency: Repeat CTx testing every 3-6 months during initial treatment phase to assess therapy response; then every 6-12 months for ongoing surveillance and long-term management
- Advanced imaging: High-resolution CT, vertebral fracture assessment (VFA), or MRI if secondary osteoporosis suspected or complicated fracture patterns noted
Fasting Required?
- Fasting requirement: Yes - fasting is recommended but not absolutely required; however, fasting improves test standardization and comparability
- Fasting duration: Minimum 8-12 hours before blood draw; overnight fasting is preferred for most consistent results
- Timing of collection: Early morning sampling (7-9 AM) preferred as CTx demonstrates diurnal rhythm with highest values at night and lowest values in afternoon
- Fluid intake: Water may be consumed during fasting period; other fluids should be avoided
- Medications to avoid: Do not discontinue regular medications unless specifically instructed by physician; particularly important to maintain antiresorptive therapy schedule
- Bisphosphonates (alendronate, risedronate): Take as scheduled; do not take immediately before blood draw; ensure proper administration technique with upright posture
- Denosumab: Continue regular injection schedule; draw blood at least 7 days after injection if possible for most valid interpretation
- Calcium and vitamin D supplements: May continue as prescribed; optimal to draw test before morning dose if possible
- Activity restrictions: Avoid strenuous exercise 24 hours before test collection as vigorous activity may affect bone turnover marker levels
- Patient preparation: Remain seated for 5 minutes before venipuncture; inform phlebotomist of recent vigorous activity or other factors affecting bone turnover
- Sample collection container: EDTA plasma (lavender-top tube) - specific requirement for this test; proper collection technique essential to avoid hemolysis
- Storage and transport: Keep sample refrigerated at 2-8°C; process within 24 hours for optimal results; avoid freezing unless specified by laboratory
- Serial sampling consistency: Use same time of day and season for repeat testing to minimize biological variation; maintain consistent fasting duration across measurements

How our test process works!